The Evidence Summary of Drug Safety Evaluation in the Cochrane Collaboration

Abstract

Abstract: Objective To summarize the evidence related to drug safety available from the Cochrane Collaboration. Methods Electronic searching on the Cochrane Library(2009 Issue 3), the searching terms included adverse drug reaction and drug safety. Results ＆Condusion Articles related to 6 aspects including Cochrane systematic review, abstracts of non-Cochrane systematic review, clinical trials, methodological study, health technology assessment and economical evaluation, respectively, were reviewed. The safety was evaluated along with efficacy or effectiveness of drugs. Currently, there has been no specific systematic review focusing on drug safety in the Cochrane Collaboration.

Key words: The Cochrane Collaboration, drug safety, evaluation, evidence, summary

CLC Number:

R954

XIA Yun, LI Xin-xue, LIU Jian-ping. The Evidence Summary of Drug Safety Evaluation in the Cochrane Collaboration[J]. Chinese Journal of Pharmacovigilance, 2010, 7(4): 208-210.

References

[1] http://www.interscience.wiley.com/cgi-bin/mrwhome/106568753/home.
[2] http://www.mrw.interscience.wiley.com/cochrane/cochrane_clabout_contents_fs.html .
[3] Loke Y K, Price D, Herxheimer A. Chapter 14: Adverse effects. In: Higgins JPT, Green S(editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1(updated September 2008)[S]. The Cochrane Collaboration, 2008.
[4] Zhang W Y. Evidence from case-control and cohort studies for adverse drug reaction - a case study of analgesic nephropathy[R].9th Annual Cochrane Colloquium Abstracts, 2001.
[5] Golder S, Loke Y, McIntosh H. Going beyond MEDLINE - what information might reviewers find from searching databases of adverse drug reactions?[J].XIV Cochrane Colloquium, 2006, 10: 23-26;Dublin, Ireland. 2006,44.
[6] Nilsson BS. Evaluation of methods for recording adverse drug reactions in clinical trials[J]. European Journal of Clinical Microbio-logy & Infectious Disease, 1990,89(7):534-536.
[7] Wallin J, Sjovall J. Detection of adverse drug reactions in a clinical trial using two types of questioning [J]. Clinical Therapeutics, 1981,3(6):450-452.
[8] Agbabiaka T B, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review[J]. Drug safety, 2008,31(1):21-37.
[9] Aronson J K, Derry S, Loke Y K. Adverse drug reactions: keeping up to date[J]. Fundamental & Clinical Pharmacology, 2002,16(1):49-56.
[10] Venulet J, Blattner R, Von Bulow J, et al. How good are articles on adverse drug reactions?[J]BMJ,1982,284(6311):252-254.
[11] Loke Y K, Price D, Derry S, et al. Case reports of suspected adverse drug reactions-systematic literature survey of followup[J]. BMJ, 2006,332(7573):335-339.
[12] Hazell L, Shakir S A. Under-reporting of adverse drug reactions: a systematic review[J]. Drug Safety, 2006,29(5):385-396.

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[3]	MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
[4]	FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
[5]	ZHANG Qi, CHEN Min, ZHANG Shiqing. Conditional approval of medical devices in the United States and enlightenment [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
[6]	CHEN Jie, QIN Kan. Evaluation of individualized parenteral nutrition delivery [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 812-816.
[7]	YU Lecheng, HAO Kunyan, FAN Ye. Clinical diagnosis of Chinese-herbal-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 481-488.
[8]	NIE Xiaolu, TANG Shaowen, YU Jinyang, SONG Haibo, FU Zhu, SUN Feng. Interpretations of reporting recommendations intended for pharmaceutical risk minimization evaluation studies(RIMES) statement [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 524-529.
[9]	YUE Xiaolin, LU Song, ZHANG Lan. Research in the construction of comprehensive evaluation systems of drugs in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 530-535.
[10]	LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping. Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
[11]	LIU Huan, YUAN Hui, YIN Jingjing, LIU Mengya, QIN Xiujun, LI Jianguo. General toxicology of Yiya Jianpi jel among juvenile animals [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 416-422.
[12]	LIU Jing, LIU Yan, ZHENG Xiaowei, WANG Qi, HE Fengyan, WANG Feifei, WANG Yadan, HE Yi, NIE Lixing, HU Xiaoru, DAI Zhong, MA Shuangcheng. Quality analysis of Guci tablets based on national drug evaluation sampling [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 292-295.
[13]	WANG Yadan, YAN Jiangong, CHEN Minghui, PANG Yu, DAI Zhong, MA Shuangcheng. UPLC fingerprints of tripterygium glycosides tablets from different manufacturers [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 146-151.
[14]	WANG Jiaqing, WANG Qi, ZHANG Dongjie, MEI Shenghui, NING Xiao. Uncertainty evaluation on the determination of norvancomycin in human cerebrospinal fluid by UPLC-MS/MS [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1346-1350.
[15]	KE Bingbing, LI Yan, WANG Pinghui, XU Xiaoling, SHEN Jiate, LYU Xiaojun. Evaluation of anaphylactoid reactions induced by human immunoglobulin for intravenous injection(pH 4.0) based on mouse auricular blue staining experiments [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1357-1361.